Oklo (OKLO) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Thank you for standing by. My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oklo First Quarter twenty twenty five Financial Results and Business Update Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Sam Doane, Director of Investo ...

Marchex (MCHX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 I'll now hand the call over to Trevor Caldwell, Senior Vice President of Investment Relations and Strategic Initiatives. You may proceed. Speaker1 Thank you, Joel. Good afternoon, everyone, and welcome to Marchex's business update and first quarter twenty twenty five conference call. Joining us today are Edgar Miller, our CEO Russ Horowitz, our Chairman of the Board and Brian Nagel, our SVP, Corporate Controller. Before we get started, I ...

Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Welcome to the Lexicon Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, 05/13/2025. I will now turn the call over to Lisa DiFrancesco, SVP, Investor Relations and Corporate Communications for ...

Kopin (KOPN) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good day, everyone, and welcome to the Kopin Corporation's First Quarter twenty twenty five Earnings Call. Please note that this event is being recorded. At this time, I'd like to turn the conference over to Brian Prineveau, Investor Relations for Kopen. Please go ahead. Speaker1 Thank you, and good afternoon, everyone. Before we get started, I'd like to remind everyone that during today's call, taking place on 05/13/2025, we will be makin ...

KinderCare Learning Companies (KLC) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 It is now my pleasure to introduce Olivia Keer, KinderCare's VP of Investor Relations. Ms. Keer, you may begin your conference. Speaker1 Thank you, and good evening, everyone. Welcome to KinderCare's first quarter earnings call. Joining me from the company are our Chief Executive Officer, Paul Thompson and Chief Financial Officer, Tony Amandy. Following Paul and Tony's comments today, we will have a question and answ ...

IZEA Worldwide (IZEA) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Greetings, and welcome to the IZEA Worldwide First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Matt Gray, Vice President of Marketing. Please go ahead. Speaker1 Good afternoon, everyone, and welcome to IZEA's earnings call cov ...

IRIDEX (IRIX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the First Quarter twenty twenty five IRIDEX Earnings Conference Call. All lines have been placed on mute to prevent any background noise. Thank you. I would now like to turn the conference over to Trip Taylor of Investor Relations. You may begin. Speaker1 Thank you, and thank ...

GEN Restaurant Group (GENK) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Please also note today's event is being recorded. At this time, I would like to turn the floor over to Tom Kearl, the company's Chief Financial Officer. Sir, you may begin. Speaker1 Thank you, operator, and good afternoon. By now, everyone should have access to our first quarter twenty twenty five earnings release. If not, it can be found at www.jenkoreanbbq.com in the Investor Relations section. Before we begin our formal r ...

Fathom (FTHM) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good day, everyone, and welcome to the Fathom Holdings, Inc. First Quarter twenty twenty five Conference Call. At this time, all participants have been placed on a listen only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Paul Kuntz. Sir, the floor is yours. Speaker1 Thank you and good afternoon. Welcome to Fathom Holdings first quarter t ...

Financial Data and Key Metrics Changes - The company reported total revenues of approximately $555 million for Q1 2025, which included cabozantinib franchise net product revenues of $513.3 million, a 36% year-over-year increase from $378 million in Q1 2024 [7][13] - Non-GAAP net income for Q1 2025 was approximately $179.6 million, or $0.64 per share basic, compared to $159.6 million GAAP net income [16] - The company increased its full-year 2025 net product revenue guidance to $2.05 billion to $2.15 billion, reflecting a $100 million increase from previous guidance [18] Business Line Data and Key Metrics Changes - The U.S. cabozantinib franchise net product revenues grew 36% year-over-year to $513 million [7] - Global cabozantinib franchise net product revenues were approximately $680 million in Q1 2025, compared to $559 million in Q1 2024 [7] - The gross-to-net for the cabozantinib franchise in Q1 2025 was 28.9%, higher than the previous quarter, primarily due to increased PHS and 340B volumes [13] Market Data and Key Metrics Changes - CABOMETYX grew its market share from 40% to 44% in the TKI market basket, with TRx volume growing 18% year-over-year [20][21] - New prescription share for CABOMETYX increased from 38% to 43%, with NRx volume growing 27% year-over-year [22] - The oral market opportunity for neuroendocrine tumors in 2025 is forecasted to be approximately $1 billion in the U.S. [24] Company Strategy and Development Direction - The company aims to build a multi-compound, multi-franchise oncology enterprise, focusing on improving the standard of care for cancer patients [4][5] - The launch of CABOMETYX in neuroendocrine tumors is seen as a significant commercial opportunity, with expectations of rapid establishment as a market leader [20][25] - The company is advancing ZANZA as its next oncology franchise opportunity, with several pivotal trials expected to report data in the second half of 2025 [10][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong performance of CABOMETYX and the potential for new indications to drive further growth [6][9] - The company is focused on advancing new molecules from its pipeline and expects to file up to three new INDs in 2025 [11][34] - Management highlighted the importance of capital allocation, balancing investments in R&D, business development, and share repurchases [12][86] Other Important Information - The company repurchased approximately $289 million of its shares during Q1 2025, with a remaining authorization of $5.5 million under the previous buyback plan [17] - The company is focused on late-stage assets in GU and GI oncology for business development opportunities [72] Q&A Session Summary Question: What has been driving CABOMETYX growth? - The company noted significant growth in market share and volume, particularly in frontline RCC, driven by positive physician feedback and updated data from CheckMate 9ER [42][46] Question: What are the expectations for the NET launch? - Management indicated that it is early days for the NET launch, with positive prescriber excitement and new prescriptions being tracked closely [49][54] Question: What is the impact of Medicare Part D redesign? - The company reported minimal impact from the redesign, with a roughly equal split between commercial and Medicare business [74][78] Question: What is the company's approach to business development? - The company remains open to business development opportunities, focusing on high-conviction assets that align with its oncology franchise [68][70]